REFERENCES
1. Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, et al. Side effect burden of antipsychotic drugs in real life-Impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry 2018;82:263-71.
2. McCutcheon R, Beck K, D’Ambrosio E, Donocik J, Gobjila C, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand 2018;137:39-46.
3. Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry 2019;6:418-26.
4. Ruan CJ, Zang YN, Wang CY, Cheng YH, Sun C, et al. Clozapine metabolism in east Asians and caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review. J Clin Psychopharmacol 2019;39:135-44.
5. Kurylev AA, Brodyansky VM, Andreev BV, Kibitov AO, Limankin OV, et al. The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study). Psychiatr Danub 2018;30:157-63.
6. Mas S, Gassò P, Alvarez S, Parellada E, Bernardo M, et al. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 2012;12:255-9.
7. Kirchheiner J, Gründemann D, Schömig E. Contribution of allelic variations in transporters to the phenotype of drug response. J Psychopharmacol 2006;20:27-32.
8. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004;25:423-9.
9. Bruckmueller H, Martin P, Kähler M, Haenisch S, Ostrowski M, et al. Clinically relevant multidrug transporters are regulated by microRNAs along the human intestine. Mol Pharm 2017;14:2245-53.
10. van der Weide K, van der Weide J. The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol 2015;35:228-36.
11. Filipce A, Naumovska Z, Nestorovska AK, Sterjev Z, Brezovska K, et al. Evaluation of correlation between the pharmacogenetic profiles of risperidone treated psychiatry patients with plasma and urine concentration of risperidone and its active moiety 9-OH rsperidone determined with optimized bioanalytical LC method. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2018;39:97-106.
12. Bakken GV, Molden E, Hermann M. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 2015;37:256-61.
13. Suzuki T, Mihara K, Nakamura A, Kagawa S, Nagai G, et al. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2014;36:651-5.
14. González-Vacarezza N, Dorado P, Peñas-Lledó EM, Fariñas H, Estévez-Carrizo FE, et al. MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers. Drug Metabol Drug Interact 2013;28:163-6.
15. van de Bilt MT, Prado CM, Ojopi EP, Sousa RT, Loch AA, et al. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment. Schizophr Res 2015;168:587-8.
16. Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo C, et al; Spanish Consortium of Pharmacogenetics Research in Schizophrenia. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics 2013;23:627-30.
17. Papazisis G, Goulas A, Sarrigiannidis A, Bargiota S, Antoniadis D, et al. ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting. Hum Psychopharmacol 2018;33.
18. Vijayan NN, Mathew A, Balan S, Natarajan C, Nair CM, et al. Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective. Pharmacogenomics 2012;13:1119-27.
19. Kastelic M, Koprivsek J, Plesnicar BK, Serretti A, Mandelli L, et al. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:387-92.
20. Suzuki Y, Tsuneyama N, Fukui N, Sugai T, Watanabe J, et al. Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia. Pharmacogenomics J 2014;14:452-6.
21. Grădinaru R, Andreescu N, Nussbaum L, Suciu L, Puiu M. Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients. Ir J Med Sci 2019;188:1417-22.
22. Ivanova SA, Filipenko ML, Vyalova NM, Voronina EN, Pozhidaev IV, et al. CYP1A2 and CYP2D6 gene polymorphisms in schizophrenic patients with neuroleptic drug-induced side effects. Bull Exp Biol Med 2016;160:687-90.
23. Hattori S, Suda A, Kishida I, Miyauchi M, Shiraishi Y, et al. Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia. BMC Psychiatry 2018;18:231.
24. Arranz MJ, Gonzalez-Rodriguez A, Perez-Blanco J, Penadés R, Gutierrez B, et al. A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. Transl Psychiatry 2019;9:177.
25. Frahnert C, Rao ML, Grasmäder K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J Chromatogr B 2003;794:35-47.
26. Leucht S, Samara M, Heres S, Patel MX, Furukawa T, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 2015;41:1397-402.
27. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 1987;13:261-76.
28. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007;318:1382-3.
29. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
30. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234-42.
31. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the clinical pharmacogenetics implementation consortium (CPIC). Genet Med 2017;19:215-223.
32. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group. Clin Transl Sci 2020;13:116-24.
33. Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, et al. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 2010;66:1109-17.
34. Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, et al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol 2016;72:175-84.
35. Czerwensky F, Leucht S, Steimer W. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. Ther Drug Monit 2015;37:152-60.
36. Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009;29:319-26.
37. Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, et al. Potential role of patients’ CYP3A-status in clozapine pharmacokinetics. Int J Neuropsychopharmacol 2017;20:529-37.
38. Huang HC, Lua AC, Wu LS, Wu BJ, Lee SM, et al. Cigarette smoking has a differential effect on the plasma level of clozapine in Taiwanese schizophrenic patients associated with the CYP1A2 gene-163A/C single nucleotide polymorphism. Psychiatr Genet 2016;26:172-7.
39. Rafaniello C, Sessa M, Bernardi FF, Pozzi M, Cheli S, et al. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J 2018;18:422-30.
40. Nikisch G, Baumann P, Oneda B, Kiessling B, Weisser H, et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol 2011;25:896-907.
41. Piatkov I, Caetano D, Assur Y, Lau SL, Coelho M, et al. CYP2C19*17 protects against metabolic complications of clozapine treatment. World J Biol Psychiatry 2017;18:521-7.
42. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, et al. Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 2000;855:235-43.
